LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 51.29% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 53.49M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 57.70.
Fairly Valued
The company’s latest PE is -2.95, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.77M shares, increasing 4.23% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 563.58K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.07.